



ELFA MEDICAMENTOS S.A.

Publicly-Held Company with Authorized Share Capital
Corporate Taxpayer ID (CNPJ) No. 09.053.134/0001-45
Company's Registry (NIRE) 53.300.018.774 | CVM Code No. CVM Nº 02534-8

NOTICE TO THE MARKET

ELFA MEDICAMENTOS S.A. ("Company"), in compliance with the provisions of Law No. 6,404, of December 15, 1976 and the regulations of the Brazilian Securities and Exchange Commission ("CVM"), in particular CVM Instruction No. 358, of January 3, 2002, notices its shareholders and the market in general that on December 07, 2021 the Company was approved in the 2020-2021 edition of the Pro-Ethics Company Program, of the Office of the Comptroller General (CGU), which recognizes companies committed to voluntarily adopting integrity measures aimed at preventing, detecting and remedying acts of fraud and corruption.

The program, which in this 2020-2021 edition celebrates its 10th anniversary, brings together the efforts of the public and private sectors to promote a corporate environment with greater integrity, ethics, and transparency. Of the 327 companies that requested access to the program, only 67 obtained the seal, a number almost three times higher than in the last edition. The award ceremony was held in Brasília and was attended by CGU minister Wagner Rosário, executive secretary of the Controller's Office, José Marcelo Castro de Carvalho, secretary of Transparency and Corruption Prevention, Roberto Viegas, and the president of Apex-Brasil, Augusto Pestana.

"To be a company with the highest ethical standards one must be truly committed and work hard, because this is a process that must be rooted in the culture and in the daily routine of the entire team. This recognition positions the Company at a high level in relation to other players in the market, besides generating confidence for our customers, suppliers, shareholders, employees, patients, and also society as a whole. In this year we had significant achievements in terms of compliance and this makes us very happy and reinforces the performance of a group that has ethics as part of its DNA.", emphasizes Elfa's Legal and Compliance Officer, Janaína Pavan.

São Paulo, December 9th, 2021.

ELFA MEDICAMENTOS S.A.

Michael Gordon Findlay
Chief Financial and Investor Relations Officer